In addition, in our previous work, in the brain of hemilesioned PD animals, the increase of PPARβ/δ was paralleled by a rise in pro-BDNF and activation of death pathways [23], thus suggesting the potential use of a PPARβ/δ antagonist in counteracting primary and possibly secondary PD symptoms. Here, PPARD is linked to Parkinson disease.